Navigation Links
Regeneron Announces Panel Discussion at Citi's 5th Annual Biotech Day
Date:9/28/2010

TARRYTOWN, N.Y., Sept. 28 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will participate in a webcast panel discussion on the topic "Eye Diseases: Novel Therapies for Wet AMD, Retinal Vein Occlusion and Diabetic Macular Edema" at Citi's 5th Annual Biotech Day on Tuesday, October 5, 2010.  The panel discussion will be broadcast live at 8:00 a.m. Eastern Time and may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page.  An archived version of the presentation will be available after the live webcast through November 4, 2010.  

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com. Contact Information:Michael Aberman, M.D.Investor Relations914.345.7799michael.aberman@regeneron.comPeter DworkinCorporate Communications914.345.7800peter.dworkin@regeneron.com
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014 Women everywhere know how ... not only uncomfortable, they,re often also embarrassing and have ... Feminine Health Support ( http://ph-defense.com ) is a new, ... an all-natural, homeopathic product. Odor, discharge, ... of vaginal infection. In many cases, the cause of ...
(Date:9/17/2014)... 2014  Aratana Therapeutics, Inc. (NASDAQ: ... licensing, developing and commercializing innovative biopharmaceutical products for ... public offering of 4,500,000 shares of its common stock at ... share. Aratana has granted the underwriters a 30-day ... shares of its common stock. Jefferies ...
(Date:9/17/2014)... , Sept. 17, 2014  Neuraltus Pharmaceuticals, Inc. announced ... 2 clinical program of NP001 for the treatment of ... disease) are being highlighted today in an oral presentation ... Group , being held in Bloomington, Minnesota ... hoc  analysis, administration of a high dose of NP001 ...
Breaking Medicine Technology:New Product from Vireo Systems: pH-D Feminine Health Support 2Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3
... (ASH) Annual Meeting ... Publication Number: 840, ... thromboses (blood clots),and transfusion requirements in patients with a rare ... have,been expected to have less severe disease, according to data ...
... Mich., Dec. 10 CSG/SportsCoatings and,the National Wrestling ... the most proactive and proven method of controlling,bacteria, ... Nationally renowned for its Sports Antimicrobial System (R) ... on all types of,athletic surfaces and fabrics for ...
Cached Medicine Technology:PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 2PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 3PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 4PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 5PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 6PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 7PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 8National Wrestling Coaches Association Teams Up With CSG/SportsCoatings(TM) 2
(Date:9/17/2014)... Social networking sites can help people lose weight, according ... obese, sites like Twitter and Facebook can be an ... well as peers, researchers found. "One advantage of ... offers the potential to be much more cost effective ... approaches," the study,s lead author, Dr. Hutan Ashrafian, a ...
(Date:9/17/2014)... North Central Surgical Center is proud to ... their top-notch services. The hospital was the recipient for ... surgery. , Hospital-wide, North Central was the recipient of ... this award for two years in a row (2013-2014). ... the nation for Patient Safety in 2014 and ranked ...
(Date:9/17/2014)... Dennis Thompson HealthDay Reporter ... in the womb to household chemicals known as phthalates ... Columbia University researchers reported in a new study. ... developing asthma between age 5 and 11 if their ... two phthalates (pronounced thal-ates), the researchers found. The two ...
(Date:9/17/2014)... this month for the November elections, one of the ... out the chamber door will be the Sustainable Growth ... of 2014. In a new commentary in the journal ... he and other advocates saw as the merits of ... Medicare pays doctors will return for the next Congress, ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Boston ... to create a monthly concert series, introducing young ... From the Top, America’s premier national platform celebrating ... musicians. Many of the young musicians featured will ... , “Boston Children’s Museum is fortunate to partner ...
Breaking Medicine News(10 mins):Health News:Social Networking Sites Can Help Obese Lose Weight: Study 2Health News:North Central Surgical Center Receives Several Accolades 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:Failed Medicare payments law remains relevant 2Health News:Failed Medicare payments law remains relevant 3Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 3
... ... latest innovations of the worldwide web to reach out to those considering plastic surgery ... updated blog, Dr. Kalus opens a virtual doorway into his practice for web visitors. ... (Vocus) September 11, 2009 -- ...
... ... is now working for his father,s personal injury law practice. In his first 18 months ... ... 2009 -- Timothy Anderson, Jr., Tampa attorney, has joined his father,s law practice. In ...
... , , , , ... is how Dr. Eliscer Guzman and The Mount Sinai Medical Center ... , a collaborative educational outreach program which was designed specifically ... , , Twenty-five patients from The Mount ...
... , , TEMECULA, Calif., Sept. 10 Patient ... a contract with Partners HealthCare and will be implementing its Safety-Sponge(TM) ... "Brigham & Women,s has a long tradition of innovation and ... are proud of the patient safety research we have done together ...
... , NEW YORK, Sept. 10 ... recognized eldercare and family caregiving expert and Founder and CEO of ... , , As healthcare reform is being debated in ... family caregiving are being overlooked. Some 30 million U.S. baby boomers are ...
... ST. PAUL, Minn., Sept. 10 The need for blood ... donor every two seconds. But right now, Memorial Blood Centers is facing ... to meet the needs of our 30 local hospital partners operating in ... , Due to existing patient needs and Standard Operating Procedures ...
Cached Medicine News:Health News:Columbia, South Carolina Plastic Cosmetic Surgeon Gives his Website a State-of-the-Art Lift 2Health News:Columbia, South Carolina Plastic Cosmetic Surgeon Gives his Website a State-of-the-Art Lift 3Health News:Tampa Personal Injury Lawyer Timothy Anderson, Jr. Joins Father's Law Firm, Takes Five Cases To Jury Trial In First Eighteen Months 2Health News:Dr. Eliscer Guzman, with The Mount Sinai Medical Center, Join Forces to Celebrate the Community Diabetes and Cardiovascular Care Program's Graduation Ceremony on September 16th 2Health News:Medicare's Missing Link: Care Coordination and Family Caregiving, by Dan Tobin, M.D., CEO of Care Support of America 2Health News:Medicare's Missing Link: Care Coordination and Family Caregiving, by Dan Tobin, M.D., CEO of Care Support of America 3Health News:Medicare's Missing Link: Care Coordination and Family Caregiving, by Dan Tobin, M.D., CEO of Care Support of America 4Health News:Memorial Blood Centers Issues a Critical Alert For Blood Donations 2
For the quantitative in vitro determination of Microalbumin in urine....
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Determination of Activated Partial Thromboplastin Time (APTT) by STA Analyzers. Cephalin reagent with kaolin activator....
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Medicine Products: